-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Parkinson's disease is a chronic neurodegenerative disease affecting the central nervous system, primarily the motor nervous system
.
Its symptoms usually appear slowly over time, with tremors, limb stiffness, decreased motor function, and abnormal gait being the most obvious early symptoms, and cognitive and behavioral problems may also be present; dementia is fairly common in severely ill patients, with more than three Major depressive disorder and anxiety disorders also occur in about one in two cases
.
Recently, the pharmaceutical company Cerevance announced the latest results of the Phase II trial of the oral drug CVN424 in the treatment of Parkinson's disease
.
Cerevance focuses on the treatment of disorders of the brain and central nervous system (CNS)
.
Figure 1.
Molecular formula of CVN424
The drug was tested in a Phase II, randomized, double-blind, placebo-controlled, multicenter study involving approximately 135 Parkinson's disease patients
.
Patients received low-dose, high-dose CVN424 or a placebo in addition to standard Parkinson's disease medications such as levodopa
.
In addition to meeting safety endpoints, CVN424 was able to significantly reduce the time to recurrence of Parkinson's symptoms, known as "off time
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https:// Leave a comment here